These findings indicate that PU.1 inhibition attenuates the vulnerability to AF and AF duration induced by Ang‐II, and the mechanisms underlying these effects may be related to the reduced activation of TGF‐β1/Smads pathway. The gene discussed is SPI1; the disease is atrial fibrillation.